Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, 7SL, cytoplasmic 126, pseudogene (RN7SL126P) is a genomic locus classified as a pseudogene—a defective copy of the RNA, 7SL, cytoplasmic gene. It arises from the genomic integration of a retrotransposed 7SL RNA sequence but lacks evidence of transcriptional activity, protein-coding potential, or biological/therapeutic function. Functional 7SL RNA is an essential part of the signal recognition particle (SRP) ribonucleoprotein complex, mediating co-translational targeting of nascent secretory and membrane proteins to the endoplasmic reticulum[1][4][6]. However, RN7SL126P itself, as a pseudogene, does not contribute to SRP activity, cellular signaling, or disease pathology. Pseudogenes like RN7SL126P are mainly of genomic and evolutionary interest—they may serve as sequence markers for retrotransposition events but do not have roles in signal transduction, cell cycle control, or therapeutic targeting[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 7SL, cytoplasmic 126, pseudogene (RN7SL126P).